Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Subscribe To Our Newsletter & Stay Updated
